Prognostic value of HLA class I expression in patients with colorectal cancer by Yuji Iwayama et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Iwayama et al. World Journal of Surgical Oncology  (2015) 13:36 
DOI 10.1186/s12957-015-0456-2RESEARCH Open AccessPrognostic value of HLA class I expression in
patients with colorectal cancer
Yuji Iwayama1, Tetsuhiro Tsuruma1*, Toru Mizuguchi1, Tomohisa Furuhata1, Nobuhiko Toyota1,
Masayuki Matsumura1, Toshihiko Torigoe2, Noriyuki Sato2 and Koichi Hirata1Abstract
Background: Prognostic factors are useful for determination of the therapeutic strategy and follow-up examination
after curative operation in cancer treatment. The immunological state of the host can influence the prognosis for
cancer patients as well as the features of the cancer. Human lymphocyte antigen (HLA) class I molecules have a
central role in the anti-cancer immune system. Therefore, we focused on the HLA class I expression level in cancer
cells to investigate its prognostic value in patients with colorectal cancer.
Methods: We reviewed the clinical pathology archives of 97 consecutive patients with stage II colorectal cancer
who underwent curative operation at the Sapporo Medical University, Japan, from February 1994 to January 2005.
Fifty-six high-risk patients had adjuvant chemotherapy. The cancer cell membrane immunoreactivity level for HLA
class I expressed by EMR8-5 was classified into three categories (positive, dull, and negative). In this study, the cases
were divided into two groups: “positive” and “dull/negative”. HLA class I expression level and clinicopathological
parameters were evaluated with the Pearson χ2 test. Survival analysis was assessed by the Kaplan-Meier methods,
and the differences between survival curves were analyzed using the log-rank test.
Results: Immunohistochemical study of HLA class I revealed the following. There were 51 cases that were
positive, 40 were dull, and six negative. The HLA class I expression level had no significant correlation with
other clinicopathological parameters, except for gender. Univariate and multivariate analyses related to disease-free
survival (DFS) revealed that tumor location, HLA expression level, and venous invasion were significant independent
prognostic factors (P < 0.05). The 5-year DFS rates in HLA class I positive group and in the dull/negative group were
89% and 70%, respectively. For high-risk patients with adjuvant chemotherapy, the 5-year DFS rates in the HLA class I
positive group and in the dull/negative group were 84% and 68%, respectively. For low-risk patients without the
chemotherapy, the
5-year DFS rates in the HLA class I positive group and in the dull/negative group were 100% and 71%, respectively.
Conclusions: Our study concluded that the HLA class I expression level might be a very sensitive prognostic factor in
colorectal cancer patients with stage II disease.
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Recently, the number of patients with colorectal cancer
is increasing. Colorectal cancer is the third most com-
mon cancer and the fourth most frequent cause of can-
cer death worldwide [1]. In Japan, colorectal cancer is
the third leading cause of cancer-related death.
The prognosis is related to many histopathological and
clinical parameters, with the most important prognostic
factor affecting survival for patients undergoing curative
operation being the presence or absence of regional
lymph node involvement [2]. Therefore, it is generally
recommended that patients with stage III colorectal can-
cer, which includes regional lymph node metastases,
should undergo adjuvant chemotherapy. However, con-
troversy still exists regarding the necessity of adjuvant
chemotherapy for node-negative patients with stage II
disease [3]. The QUASAR trial demonstrated that adju-
vant chemotherapy with fluorouracil/leucovorin (FU/LV)
could improve survival of patients with stage II colorec-
tal cancer, although the absolute improvements were
small [4]. Pooled analysis (IMPACT B2) of randomized
trials comparing groups with adjuvant chemotherapy
receiving FU/LV and those with surgery alone demon-
strated that there was no significant difference in event-
free and overall survival [5]. Meanwhile, O’Connor et al.
reported that no 5-year survival benefit from adjuvant
chemotherapy was observed for patients with stage II
disease, although a benefit was observed for those with
stage III disease [6]. In the present situation, adjuvant
chemotherapy is conducted for patients categorized into
a high-risk group among those with stage II disease on
the basis of various histopathological or clinical parame-
ters such as poorly differentiated histology, lymphovas-
cular invasion, perineural invasion, T4 tumor stage,
bowel obstruction or perforation, and an elevated pre-
operative plasma level of carcinoembryonic antigen
(CEA) [7]. These parameters are indicated in some
guidelines such as the National Comprehensive Cancer
Network (NCCN), European Society for Medical
Oncology (ESMO), etc. [8], although they are not based
on conclusive evidence.
The immune system discriminates between self and
nonself, targeting, for example, cancer cells. However,
cancer cells can escape from the immune system and
grow, metastasize, and finally cause death. One mechan-
ism of the immune escape by cancer development is the
downregulation of human lymphocyte antigen (HLA)
class I molecules, which are cancer antigen-presenting
molecules for cytotoxic T lymphocytes (CTLs) [9-12].
The immune state is of great importance in the progno-
sis of cancer patients. Therefore, we focused on the
HLA class I expression level in cancer cells to investigate
its prognostic value in patients with colorectal cancer.
Since most anti-HLA class I antibodies recognize theallele-specific native structure of HLA class I molecules,
these antibodies have been unable to react with dena-
tured HLA class I molecules in formalin-fixed paraffin-
embedded tissue sections. However, we created a novel
monoclonal pan-HLA class I antibody, EMR8-5, suitable
for the immunostaining of formalin-fixed tissue speci-
mens [13]. Therefore, we are now able to retrospectively
investigate HLA class I expression levels in cancer speci-
mens that were surgically resected and stored for a long
time.
In this study, we investigated the prognostic value of




The study was approved by the Clinical Institutional
Ethical Review Board of the Medical Institute of
Bioregulation, Sapporo Medical University, Japan. We
reviewed the clinical pathology archives of 97 consecu-
tive patients with stage II (TNM classification [UICC])
colorectal cancer (61 men and 36 women; age range:
31–83 years) who underwent curative operation, defined
as the removal of all of the tumoral masses, the absence
of microscopic residual tumors, histology-negative resec-
tion margins, and lymphadenectomy extended beyond
the involved nodes at the postoperative pathologic
examination, at the Sapporo Medical University
Hospital, Sapporo, Japan, from February 1994 to January
2005. Written informed consent was obtained from each
patient according to the guidelines of the Declaration of
Helsinki. Fifty-six patients with poorly differentiated
histology or positive lymphovascular invasion had adju-
vant chemotherapy. These patients were randomly
assigned to receive 5-FU plus daily divided dose cisplatin
(5-FU, 320 mg/m2 daily for 21 days; CDDP, 3.5 mg/m2
daily for 21 days) followed by oral 5-FU (200 mg/body
daily for 2 years) or oral 5-FU therapy (200 mg/body
daily for 2 years) exclusively as randomized trial [14]. No
patients with rectal cancer had radiotherapy. Patients
whose medical reports were incomplete were excluded.
The median follow-up time was 54 months. Patients’
characteristics were assessed by tumor stage (stage IIA,
stage IIB, and stage IIC), age, gender, tumor size, tumor
location, histological type, and lymphovascular invasion.
Antibody
The monoclonal anti-pan-HLA class I antibody EMR8-5
was established at our laboratory [13]. This mouse mAb
(currently commercially available from Hokudo Co.,
Ltd., Japan) reacts with extracellular domains of HLA-
A*2402, A*0101, A*1101, A*0201, A*0207, B*0702,
B*0801, B*1501, B*3501, B*4001, B*4002, B*4006,
B*4403, Cw*0102, Cw*0801, Cw*1202, and Cw*1502 [15]
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ventional light microscopic analysis of formalin-fixed,
paraffin-embedded sections.
Immunohistochemistry
Immunohistochemical staining with the antibody was
performed on formalin-fixed, paraffin-embedded tissues
after steam heat-induced epitope retrieval. Subsequent
incubations with a secondary biotinylated antibody,
avidin-conjugated peroxidase complex, and chromogen
were carried out on a Ventana NexES (Ventana Medical
Systems, Inc., Tucson, AZ) [16]. Slides were then coun-
terstained with hematoxylin, rinsed, dehydrated through
graded alcohols into nonaqueous solution, and cover-
slipped with mounting media. Positive reactivity to
EMR8-5 was confirmed by staining of vascular endothe-
lial cells and lymphocytes in sections of tumor speci-
mens [15].
Evaluation of HLA class I expression
The cancer cell membrane immunoreactivity level for
HLA class I expressed by EMR8-5 was classified into
three categories (positive, dull, and negative). Positive
was defined as complete and heterogeneous membrane
staining in more than 80% of the tumor cells (Figure 1a).
Dull was defined as faint, incomplete, and heterogeneous
membrane staining in 20% ~ 80% of the tumor cells
(Figure 1b). Negative was defined as membrane staining
in less than 20% of the tumor cells (Figure 1c). All speci-
mens were reviewed independently using light micros-
copy in at least five areas at × 200 magnification by two
investigators who were blinded to the clinicopathological
data (TT and YI).
Statistical analysis
We investigated the relationships between HLA class I
expression levels and the other parameters (age, gender,Figure 1 Representative picture of immunostaining with the antibody
class I, which was expressed by EMR8-5, was classified into three categories
heterogeneous membrane staining in more than 80% of the tumor cells. D
staining in 20% ~ 80% of the tumor cells. Negative was defined as membra
and (c) negative.tumor location, tumor size, depth, histological type, lym-
phovascular invasion, budding, number of lymph nodes
analyzed after surgery (<12), HLA class I expression
level, and adjuvant chemotherapy) and clinical outcome
(disease-free survival: DFS). Some of these parameters
(depth, histological type, lymphovascular invasion, bud-
ding, number of lymph nodes analyzed after surgery
(<12)) were recommended as potential prognostic fac-
tors for curatively resected colorectal cancer by ESMO
guidelines [8] or NCCN Guidelines Version 2 (2014).
Statistical analysis was performed using SPSS Statistics
17.0. Deviation between the HLA class I expression level
and clinicopathological parameters was evaluated with
the Pearson χ2 test. Survival analysis was assessed by the
Kaplan-Meier method, and the differences between sur-
vival curves were analyzed using the log-rank test. To
evaluate the correlations between the survival rate and
clinicopathological parameters, univariate and multivari-
ate regression analyses according to the Cox propor-
tional hazards regression model were used. A P value
<0.05 was considered to indicate statistical significance.
Results
HLA class I expression level and patient characteristics in
patients with stage II colorectal cancer
Immunohistochemical study of HLA class I in cancer
cells revealed the following. There were 51 cases (53%)
that were positive, which was defined as complete and
heterogeneous membrane staining in more than 80% of
the tumor cells, as well as 40 (41%) that were dull, which
was defined as faint, incomplete, and heterogeneous
membrane staining in 20% ~ 80% of the tumor cells, and
six (6%) that were negative, which was defined as mem-
brane staining in less than 20% of the tumor cells. In this
study, the cases were divided into two groups, those that
were “positive” (n = 51) and those that were “dull and
negative” (n = 46). The relationships between HLA classEMR8-5. The cancer cell membrane immunoreactivity level for HLA
(positive, dull, and negative). Positive was defined as complete and
ull was defined as faint, incomplete, and heterogeneous membrane
ne staining in less than 20% of the tumor cells. (a) Positive, (b) dull,
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stage (stage IIA, stage IIB, and stage IIC), age, gender,
tumor size, tumor location, histological type, and lym-
phovascular invasion, were assessed. The HLA class I
expression level had no significant correlation with other
clinicopathological parameters, except for gender
(Table 1).
Prognostic factors in patients with stage II colorectal
cancer
Univariate analysis related to DFS revealed that the
tumor location (P = 0.01) and HLA class I expression
level (P = 0.02) might be significant prognostic factors
among age, gender, tumor location, tumor size, depth,
histological type, lymphovascular invasion, budding,
number of lymph nodes analyzed, HLA class I expres-
sion level, and adjuvant chemotherapy. It also suggested
that venous invasion might be a prognostic factorTable 1 HLA class I expression levels and characteristics of th
Positive
(n = 51; 53%)
Stage
Stage IIA 46 (90)
Stage IIB 2 (4)
Stage IIC 3 (6)
Age (years)
Mean ± SD 64 ± 9.7
Range 42 ~ 80
Gender—no. of patients (%)
Male 27 (53%)
Female 24 (47%)











Lymphatic invasion—no. of patients (%)
Negative 45 (88%)
Positive 6 (12%)
Venous invasion—no. of patients (%)
Negative 44 (86%)
Positive 7 (14%)(P = 0.05). Moreover, multivariate analysis revealed
that tumor location, HLA expression level, and venous
invasion were significant independent prognostic factors
(P < 0.05) (Table 2).
HLA class I expression and 5-year DFS
Univariate and multivariate analyses revealed that the
HLA class I expression level might be a useful prognos-
tic factor related to DFS. Therefore, survival analysis was
conducted using the Kaplan-Meier method. The 5-year
DFS rates in the HLA class I positive group and in the
dull and negative (dull/negative) group were 89% and
70%, respectively (P = 0.01) (Figure 2).
HLA class I expression and adjuvant chemotherapy
Fifty-six stage II colorectal cancer patients with poorly
differentiated histology or positive lymphovascular inva-
sion had adjuvant chemotherapy. For patients with thise patients (stage II colorectal cancer)
Dull and negative Total P




























Table 2 Univariate and multivariate analyses related to disease-free survival in 97 colorectal cancer patients
Variables
Univariate Multivariate
Hazard ratio P value Hazard ratio P value
Age 0.98 (0.94–1.02) 0.38
Gender (F) 1.42 (0.50–4.04) 0.51
Tumor location (colon vs rectum) 4.23 (1.49–12.01) 0.01 4.11 (1.42–11.91) 0.009
Tumor size (≦5 cm) 0.64 (0.24–1.73) 0.38
Tumor invasion (SI) 0.52 (0.12–2.28) 0.39
Differentiation (por or muc) 1.50 (0.20–11.35) 0.70
Lymphatic invasion (ly0, 1 vs ly2, 3) 1.10 (0.25–4.83) 0.90
Venous invasion (v0, 1 vs v2, 3) 3.10 (1.00–9.56) 0.05 3.85 (1.15–12.92) 0.03
Budding 0.52 (0.19–1.41) 0.20
Number of lymph nodes analyzed (<12) 1.32 (0.51–3.43) 0.57
HLA expression level (dull or negative) 3.86 (1.26–11.85) 0.02 5.36 (1.68–17.11) 0.005
Adjuvant chemotherapy (no) 0.82 (0.30–2.22) 0.70
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class I positive expression and those with dull/negative
expression were compared. The 5-year DFS rates in the
HLA class I positive group and in the dull/negative
group were 84% and 68%, respectively (Figure 3). The 5-
year DFS in patients with HLA dull/negative expression
was lower than that of those with HLA positive expres-
sion, although there was no significant difference (P = 0.10).
On the other hand, no patient with HLA class I positive
expression without chemotherapy relapsed, whereas
29% of those with HLA dull/negative expression re-
lapsed. For those without adjuvant chemotherapy, there
was a significant difference in 5-year DFS between pa-
tients with HLA class I positive expression and dull/
negative expression (P = 0.03) (Figure 4).Figure 2 Five-year disease-free survival curves of stage II
colorectal cancer patients. The 5-year DFS rates in the HLA class I
positive group (black circle) and in the dull and negative group
(white circle) were 89% and 70%, respectively. Patients with HLA class
I positive expression had a significantly higher DFS rate than that of
those with HLA class I dull and negative expression (P = 0.01).Discussion
Prognostic factors are useful for determination of the
therapeutic strategy and follow-up examination after
curative operation in cancer treatment. There are vari-
ous reports of clinical and pathological prognostic fac-
tors. However, there are few immunological prognostic
factors. The immunological state of the host can influ-
ence the prognosis for cancer patients as well as the fea-
tures of the cancer.
HLA class I molecules have a central role in the anti-
cancer immune system, especially as cancer antigen-
presenting molecules for CTLs [13]. CTLs can recognize
antigenic peptides presented on the cell surface by HLAFigure 3 Five-year disease-free survival curves of patients with
adjuvant chemotherapy. The 5-year DFS rates of patients with HLA
class I positive expression (black circle) and with dull and negative
expression (white circle) were compared. The 5-year DFS in patients
with HLA dull and negative expression was decreased more than
that of those with HLA positive expression, although there was no
significant difference (P = 0.10).
Figure 4 Five-year disease-free survival curves of patients
without adjuvant chemotherapy. No patient with HLA class I
positive expression (black circle) relapsed. Twenty-nine percent of
patients with HLA dull and negative expression (white circle)
relapsed. For patients without adjuvant chemotherapy, there was a
significant difference in the 5-year DFS between patients with HLA
class I positive expression and those with dull and negative
expression (P = 0.03).
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cells. However, cancer cells can escape from the immune
system by downregulation of HLA class I molecules, se-
cretion of immunosuppressive cytokines, and infiltration
of immunosuppressive cells [9-13]. One mechanism of
recurrence after curative operation might be immune es-
cape by micrometastatic cancer cells. Therefore, we fo-
cused on HLA class I molecules, key molecules in the
immune system, to investigate the possibility of new im-
munological prognostic factors. This investigation was
enabled through the use of the novel monoclonal pan-
HLA class I antibody EMR8-5 [13], which is suitable for
the immunostaining of surgically resected, formalin-
fixed tissue specimens stored for a long time.
In this study, we investigated the HLA class I expres-
sion level and the prognoses of stage II colorectal cancer
patients who underwent curative operation. In patients
with stage II cancer, there was a significant difference in
5-year DFS between HLA class I positive patients and
dull/negative patients (P = 0.01). Patients with HLA class
I positive expression had a higher 5-year overall survival
(OS) rate than those with HLA class I dull/negative ex-
pression, although there was no significant difference
(P = 0.29) (data not shown). In addition, univariate and
multivariate analyses revealed that the HLA class I ex-
pression level might be a significant independent prog-
nostic factor. These data suggested that the HLA class I
expression level might be a useful prognostic factor,
particularly as a predictive factor for relapse, in stage II
colorectal cancer. The reason why there was no signifi-
cant difference in OS for stage II colorectal cancerpatients is speculated to be that the beneficial treat-
ments after recurrence might have more influence on
OS than the immunological state in the living body such
as the HLA class I expression level.
We have also reported that the HLA class I expression
level might be a prognostic factor for other cancers such
as osteosarcoma, clear cell renal cell carcinoma, and
bladder cancer [15-19]. Tsukahara et al. reported that
patients with osteosarcoma highly expressing HLA class
I had significantly better OS and DFS than those with
HLA class I-negative osteosarcoma [15]. Thus, there
might be a difference in the impact of the HLA class I
expression level on OS or DFS depending on the cancer.
Although most reports, including our study, suggested
that downregulation of HLA class I expression level was
associated with a poor prognosis, Madjd Z et al. re-
ported that total loss of HLA class I was an independent
indicator of good prognosis in breast cancer [20]. They
considered that the loss of HLA class I might make the
tumors more susceptible to natural killer (NK) killing
and result in a better prognostic outcome. It is due to
the presence of HLA class I allele-specific killer cell in-
hibitory receptors (KIRs) on the surface of NK cells.
Thus, in the absence of HLA class I expression, this
KIRs-mediated inhibitory signaling is lost, resulting in
the activation of NK cytolytic effector functions [21]. NK
cell-mediated cytotoxicity is regulated by a delicate bal-
ance between activating and inhibitory signals. So, the
prognostic influence brought by the HLA class I expres-
sion level might depend on the various cancer immune
circumstances.
Surgery alone has relatively favorable results in colo-
rectal cancer patients with stage II disease; hence, any
advantage conferred by adjuvant chemotherapy after the
curative operation is likely to be small. However, in real
life in Japan, approximately 13% of patients with stage II
colorectal cancer are found to have recurrence. The sev-
enth edition of the American Joint Committee on Cancer
(AJCC) Staging Manual divides stage II into three groups:
stage IIA (T3N0), stage IIB (T4aN0), and stage IIC
(T4bN0). There is a report that the prognoses for the stage
IIB and IIC subgroups are worse than those of some stage
III patients [22]. Therefore, stage II patients could be di-
vided into high- and low-risk populations. We should se-
lect high-risk stage II patients and give adjuvant
chemotherapy to prevent recurrence by micrometas-
tases only to those patients who can obtain a significant
benefit from it. The NCCN Guidelines Version 2 (2014)
recommended the following risk factors for recurrence:
number of lymph nodes analyzed after surgery (<12),
poorly differentiated histology, lymphatic/vascular inva-
sion, bowel obstruction, perineural invasion, localized
perforation, and close, indeterminate, or positive mar-
gins. The ESMO consensus guideline recommended
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differentiated tumor, vascular or lymphatic or perineu-
ral invasion, T4 stage, and clinical presentation with in-
testinal occlusion or perforation [8]. In this study,
patients with poorly differentiated tumors or moderate
and severe lymphovascular invasion were considered to
be high-risk stage II patients and underwent adjuvant
chemotherapy. We investigated the 5-year DFS in stage
II patients with and without adjuvant chemotherapy,
respectively. Patients with HLA class I positive expres-
sion had a higher DFS rate than those with HLA class I
dull/negative expression under both settings. In
addition, for low-risk patients without chemotherapy,
all patients with HLA class I positive expression did
not relapse, although 29% of those with HLA class I
dull/negative expression relapsed. These data might
make certain of the prognostic value of HLA class I ex-
pression for relapse.
Conclusions
The HLA class I expression level might be a very sensi-
tive prognostic factor in colorectal cancer patients with
stage II disease.
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